Breaking News From Pharma & Bio Ingredients
Genentech Seeks Priority Review for Lucentis
Posted on 2005-12-30 14:29:00
Genentech Inc. said Friday it is asking federal regulators to speed up the review process for a treatment designed to slow down a type of eye disease that can cause blindness.
Genentech is asking for the "priority review" for its Lucentis treatment. If granted, the FDA could act on Genentech's application within six months.
Lucentis is designed to treat an eye disease known as neovascular wet age-related macular degeneration, or wet AMD. The disease is caused by the growth of abnormal blood vessels that leak fluid and blood and cause scar tissue that destroys the eye's central retina. The result is deteriorated vision over a period of months to years, Genentech said.
Genentech is developing Lucentis with the opthalmics unit of Swiss drug giant Novartis AG.
Subscribe via RSS
